Eli Lilly (LLY) Receivables (2009 - 2026)
Eli Lilly (LLY) reported Receivables of $23.48 billion for Q2 2026, up 36.4% from $17.21 billion a year earlier and up 10.9% from the prior quarter.
Powered by 
Analysis
Eli Lilly (LLY) Receivables (2009 - 2026) Analysis & Trends
At the end of FY2025, Eli Lilly posted Receivables of $20.16 billion, up 51.8% from FY2024.
- Receivables has increased for six consecutive years, with a five-year compound annual growth rate of 23.8% (FY2020 to FY2025).
- By year, Receivables came in at $13.28 billion in FY2024 (+17.1%), $11.34 billion in FY2023 (+32.4%), $8.56 billion in FY2022 (+5.3%) and $8.13 billion in FY2021 (+17.3%).
- The Q2 2026 figure ranks as the highest quarterly Receivables in data going back to Q2 2009.
- Year over year, Receivables has now increased in each of the last 26 quarters, with growth averaging 38.2% over the last eight quarters.
- Across the past five years, year-over-year growth in Receivables ran from 5.3% in Q4 2022 to 61.4% in Q3 2025.
- Per Business Quant data, the three quarters before Q2 2026 came in at $21.18 billion (Q1 2026), $20.16 billion (Q4 2025) and $19.46 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 23.48 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 19.05 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 13.82 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 12.56 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 9.64 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 15.68 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 10.23 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 5.06 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 12.49 Bn |
| 10 | Vertex Pharmaceuticals | 133.33 Bn | 105.34 Bn | 2.84 Bn | 2.13 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.48 Bn |
| Mar 31, 2026 | 21.18 Bn |
| Dec 31, 2025 | 20.16 Bn |
| Sep 30, 2025 | 19.46 Bn |
| Jun 30, 2025 | 17.21 Bn |
| Mar 31, 2025 | 14.00 Bn |
| Dec 31, 2024 | 13.28 Bn |
| Sep 30, 2024 | 12.05 Bn |
| Jun 30, 2024 | 13.08 Bn |
| Mar 31, 2024 | 10.01 Bn |
| Dec 31, 2023 | 11.34 Bn |
| Sep 30, 2023 | 10.36 Bn |
| Jun 30, 2023 | 9.17 Bn |
| Mar 31, 2023 | 9.02 Bn |
| Dec 31, 2022 | 8.56 Bn |
| Sep 30, 2022 | 8.32 Bn |
| Jun 30, 2022 | 7.67 Bn |
| Mar 31, 2022 | 7.81 Bn |
| Dec 31, 2021 | 8.13 Bn |
| Sep 30, 2021 | 7.03 Bn |
API Access
Eli Lilly Receivables API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables&ticker=LLY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables", "ticker": "LLY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables&ticker=LLY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();